ClinicalTrials.gg
Not yet recruitingNCT07706933Updated Oct 27, 2026

Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer

An interventional study of Dalpiciclib and Abemaciclib/Ribociclib in Breast Cancer, sponsored by Henan Cancer Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Henan Cancer Hospital · Not applicable, Interventional, and Treatment

How we know · 8 judgments

Updated Oct 27, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 49 studies testing dalpiciclib in Breast Neoplasms — 30 open to participants now, 35 under way, 4 of them phase 3. dalpiciclib · Breast Neoplasms.

Planned enrollment
7th of 49
456 · median 72
Started
2026
with 5 others
No phase
5 of 49
4 open now
Primary completion
2028-06
later than 25 of 34 live
Registered
48th of 49
by date
Lead sponsor
3 of 49
Henan Cancer Hospital

Among the 49 studies testing dalpiciclib in Breast Neoplasms, this one is the 7th largest by planned enrollment, is one of 6 that started in 2026, is one of 5 with no phase, reaches primary completion later than 25 of the 34 other live ones, and was the 48th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

30 of the 49 studies testing dalpiciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

About dalpiciclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing dalpiciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

In recent years, the successful application of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for HR+/HER2- advanced breast cancer and driven research into their use in adjuvant settings. Large Phase III trials including MONARCH-E and NATALEE have demonstrated that combining CDK4/6i with standard endocrine therapy significantly reduces the risk of recurrence or death in high-risk patients with early breast cancer. This regimen has been recommended by leading domestic and international clinical guidelines. Nevertheless, patients' quality of life, symptom burden and treatment adherence are also critical in clinical practice. Patient-reported outcomes (PROs), especially electronic PROs (ePROs), can effectively complement conventional study endpoints and provide important evidence for the comprehensive evaluation of long-term treatment.

This is a prospective, multicenter, randomized controlled clinical trial. The primary objective is to compare the tolerability of dalpiciclib versus abemaciclib/ribociclib, each combined with standard endocrine therapy, in the adjuvant treatment of patients with high-risk HR+/HER2- early breast cancer. Eligible patients who have received curative local therapy will be randomized to either the experimental group (dalpiciclib plus endocrine therapy) or the control group (ribociclib/abemaciclib plus endocrine therapy). Stratified block randomization will be applied, with stratification factors including menopausal status and prior history of neoadjuvant/adjuvant chemotherapy.

The total duration of endocrine therapy is 5 years. The treatment duration of CDK4/6i is approximately 104 weeks for dalpiciclib, 156 weeks for ribociclib, and 104 weeks for abemaciclib. CDK4/6i will be discontinued in cases of disease recurrence, intolerable toxicity, patient withdrawal, or discontinuation as determined by the investigator. Patients will be regularly asked to complete ePRO questionnaires throughout the treatment period.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • HR+
  • early breast cancer
  • Dalpiciclib
  • ePRO
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years with clinical stage II-III breast cancer at the time of signing .
  2. Post-operative pathological confirmation of invasive breast cancer that is hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (-), as confirmed by the research center's pathology department:

    • ER positive and/or PR positive defined as ≥10% of tumor cells showing positive nuclear staining.

      • HER2 negative defined as immunohistochemistry (IHC) 0 or 1+, or negative by in situ hybridization (ISH).
  3. confirmed unilateral primary invasive breast cancer, with the date of breast cancer diagnosis on the pathology report no more than 18 months before randomization. For patients with multicentric or multifocal tumors, all pathologically examined lesions must meet the pathological requirements in criterion .
  4. For patients who completed or neoadjuvant chemotherapy(if applicable).
  5. For patients who completed adjuvant radiotherapy(if applicable).
  6. For patients who have initiated adjuvant endocrine therapy, randomization must be completed within 12 months of the first endocrine therapy administration date.
  7. Has undergone curative surgical resection with tumor-free margins on pathological examination, and meets one of the following high-risk categories:

    • Pathologically confirmed tumor involvement in ≥4 ipsilateral axillary lymph nodes; OR ② Pathologically confirmed tumor involvement in 1-3 ipsilateral axillary lymph nodes AND at least one of the following:

      a. Pathological primary invasive tumor size ≥5 cm; b. Primary tumor histological grade 3 (G3); c. Ki-67 ≥20%; d. Known genetic test indicating high risk of recurrence.

  8. (ECOG) performance status score of 0 or 1.
  9. No evidence of recurrence or disease after surgery.
  10. Adequate organ and bone marrow function, meeting the following criteria:

    • White blood cell (WBC) count ≥3,000/mm³ (3.0 × 10⁹/L) (without G-CSF within 14 days);

      • (ANC) ≥1,500/mm³ (1.5 × 10⁹/L) (without G-CSF within 14 days);

        • count (PLT) ≥100,000/mm³ (100 × 10⁹/L) (without corrective treatment within 7 days);

          • (Hb) ≥9 g/dL (90 g/L) (without corrective treatment within 7 days); ⑤ Serum creatinine ≤1.5 × (ULN) or ≥60 mL/min (without corrective treatment within 7 days); ⑥ Total (TBIL) ≤1.5 × ULN (without corrective treatment within 7 days); ⑦ (AST) and alanine aminotransferase (ALT) ≤3 × ULN (without corrective treatment within 7 days); ⑧ ≤470 ms.
  11. Female patients of must have a negative serum pregnancy test within 7 days before randomization, and must agree to use acceptable non-hormonal from the signing of informed consent until 7 months after the last dose of dalpiciclib, or 21 days after the last dose of abemaciclib/ribociclib, or 2 months after the last dose of aromatase inhibitor or tamoxifen/toremifene (whichever is longer).
  12. All toxicities from prior anti-cancer therapy must have recovered to grade 0-1 ( version 6.0), except for those explicitly stated in the inclusion/exclusion criteria.
  13. Has voluntarily signed the informed consent form, and is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Pathological diagnosis of -positive breast cancer (HER2-positive defined as immunohistochemistry [IHC] 3+ or positive by in situ hybridization [ISH]).
  2. Local or regional recurrence of breast .
  3. Clinical stage IV () breast cancer.
  4. Bilateral breast cancer (including contralateral carcinoma in situ).
  5. History of any malignancy other than breast cancer within 5 years before randomization, excluding adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin.
  6. History of severe pulmonary disease such as interstitial pneumonia.
  7. Prior treatment with any CDK4/6 inhibitor, other anti-cancer biologic therapy, targeted therapy, or cancer immunotherapy.
  8. Concurrent participation in another clinical trial of anti-cancer therapy (including endocrine therapy or immunotherapy).
  9. Major surgical procedure, receipt of any drug, other anti-cancer treatment, or use of immunomodulators within 4 weeks before randomization (excluding chemotherapy, radiotherapy, and endocrine therapy for breast cancer).
  10. Known infection with (HIV) or acquired immunodeficiency syndrome (AIDS); active (HBV DNA ≥500 IU/mL); (positive hepatitis C antibody with HCV-RNA above the lower limit of detection of the assay); or co-infection with hepatitis B and hepatitis C.
  11. Any of the following within 6 months before randomization: myocardial infarction, severe/unstable angina pectoris, (NYHA) class ≥2 heart failure, persistent arrhythmia of grade ≥2 (according to version 6.0), atrial fibrillation of any grade, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident (including ), or pulmonary embolism.
  12. Severe infection within 4 weeks before randomization (e.g., requiring intravenous antibiotics, antifungals, or antivirals per clinical practice guidelines), or unexplained fever >38.5°C during screening or before the first dose.
  13. Inability to swallow, intestinal obstruction, or other factors affecting drug administration or absorption.
  14. Known to aromatase inhibitors, tamoxifen-class drugs (e.g., tamoxifen, toremifene), and LHRH agonists; known hypersensitivity to dalpiciclib/abemaciclib/ribociclib or any of their
  15. History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  16. Known history of substance abuse (including psychoactive drugs).
  17. Women within 1 year postpartum or currently breastfeeding.
  18. Presence of any other serious physical or psychiatric condition, or laboratory abnormality that may increase the risk of study participation, interfere with study results, or render the patient unsuitable for the study in the opinion of the investigator.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
456 participants (estimated)

Study arms

  • Experimental
    Experimental: Dalpiciclib + Standard Endocrine Therapy

    Participants will receive Dalpiciclib 125 mg orally once daily on days 1-21 of a 28-day cycle (3 weeks on, 1 week off) for 24 months (26 cycles). In addition, participants will receive standard adjuvant endocrine therapy for 5 years. The choice of endocrine therapy depends on menopausal status: Premenopausal/perimenopausal: LHRH agonist (goserelin or leuprorelin) + aromatase inhibitor (letrozole or anastrozole) or tamoxifen/toremifene if intolerant to aromatase inhibitor. Postmenopausal: aromatase inhibitor (letrozole or anastrozole) or tamoxifen/toremifene if intolerant to aromatase inhibitor. Endocrine therapy is administered continuously every 28 days.

    Drug: Dalpiciclib

  • Active comparator
    Control:Abemaciclib/Ribociclib + Standard Endocrine Therapy

    Participants will receive either Abemaciclib or Ribociclib according to the approved product labeling for dose, administration, and treatment duration. Abemaciclib is given for 24 months; Ribociclib is given for 36 months (as per label). In addition, participants will receive the same 5-year standard adjuvant endocrine therapy as described in Arm 1, based on menopausal status. The choice between Abemaciclib and Ribociclib is at the investigator's discretion following local guidelines.

    Drug: Abemaciclib/Ribociclib

Interventions

  • Description: 125 mg orally once daily on days 1-21 of a 28-day cycle (3 weeks on, 1 week off) for 24 months (26 cycles). Receive 5 years of standard endocrine therapy. The recommended treatment drugs are as follows: Letrozole Description: 2.5 mg orally once daily continuously for 5 years as part of standard endocrine therapy. Anastrozole Description: 1 mg orally once daily continuously for 5 years as part of standard endocrine therapy. Tamoxifen Description: 10 mg orally twice daily continuously for 5 years as part of standard endocrine therapy. Toremifene Description: 60 mg orally once daily continuously for 5 years as part of standard endocrine therapy. Premenopausal: Preferred treatment is LHRH agonist plus an aromatase inhibitor. Perimenopausal: LHRH agonist and endocrine therapy may be used per investigator's assessment. Goserelin Description: LHRH agonist administered subcutaneously (e.g., 3.6 mg every 28 days) for ovarian function suppression in premenopausal/perimenopausal

  • DrugAbemaciclib/Ribociclib

    Drug pages: AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Abemaciclib Description: Administered according to approved product labeling. Typical dose: 150 mg twice daily continuously for 24 months. Investigator's choice between abemaciclib and ribociclib. Ribociclib Description: Administered according to approved product labeling. Typical dose: 400 mg orally once daily (3 weeks on, 1 week off) for 36 months. Investigator's choice between abemaciclib and ribociclib. Receive 5 years of standard endocrine therapy. The recommended treatment drugs are as follows: Letrozole Description: 2.5 mg orally once daily continuously for 5 years as part of standard endocrine therapy. Anastrozole Description: 1 mg orally once daily continuously for 5 years as part of standard endocrine therapy. Tamoxifen Description: 10 mg orally twice daily continuously for 5 years as part of standard endocrine therapy. Toremifene Description: 60 mg orally once daily continuously for 5 years as part of standard endocrine therapy. Premenopausal: Preferred treatment is LHRH

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Rate of CDK4/6 inhibitor dose reduction or permanent discontinuation due to any cause by Week 12

    Rate of CDK4/6 inhibitor dose reduction or permanent discontinuation due to any cause by Week 12

    Time frame: From randomization up to Week 12 (Day 84, ±7 days)

Secondary outcomes

  1. Health-Related Quality of Life - Time to Deterioration (HRQOL-TTD)

    Time from randomization to the first clinically meaningful deterioration (defined as a ≥10-point decrease from baseline) in global health status/quality of life score measured by the EORTC QLQ-C30 (version 3.0). Death before deterioration is handled as a competing risk event.

    Time frame: Up to 5 years (from randomization until deterioration, death, or end of study)

  2. Change in Functional Domain Scores

    Change from baseline in physical, role, cognitive, emotional, and social functioning scores measured by the EORTC QLQ-C30 at months 1, 3, 6, 12, 18, and 24. Mixed model for repeated measures (MMRM) will be used to compare trajectories between arms.

    Time frame: Baseline to month 24

  3. . Safety - Incidence and Severity of Adverse Events

    Incidence, severity (graded by NCI-CTCAE version 6.0), and duration of all-grade and grade ≥3 adverse events, serious adverse events (SAEs), adverse events leading to dose modification or treatment discontinuation, and adverse events related to study drugs.

    Time frame: From signing of informed consent until 28 days after last dose of study drug (up to approximately 5.5 years)

  4. Rate of CDK4/6 Inhibitor Dose Reduction or Permanent Discontinuation by Month 6

    Proportion of participants with a permanent dose reduction or permanent discontinuation of the CDK4/6 inhibitor due to any cause by month 6 (Day 168, window ±14 days), using the same definition as the primary endpoint.

    Time frame: From randomization up to month 6 (Day 168, ±14 days)

  5. Treatment Adherence - Median Treatment Duration and Relative Dose Intensity

    Median duration of CDK4/6 inhibitor treatment (in months) and relative dose intensity (actual delivered dose / planned dose × 100%) for each treatment arm.

    Time frame: From start of treatment to end of CDK4/6 inhibitor treatment period (up to 24 months for dalpiciclib/abemaciclib, up to 36 months for ribociclib)

  6. Health Economic Outcome - Quality-Adjusted Life Years (QALYs)

    Quality-adjusted life years calculated from EQ-5D-5L utility scores using a country-specific value set. Differences in QALYs between arms will be estimated using a generalized linear model, and incremental cost-effectiveness ratios (ICERs) will be calculated.

    Time frame: From baseline through 5 years of follow-up

  7. Invasive Disease-Free Survival (iDFS)

    Time from randomization to the first occurrence of any of the following events: invasive ipsilateral or contralateral breast cancer recurrence, local/regional invasive recurrence, distant recurrence, second primary invasive cancer (non-breast), or death from any cause.

    Time frame: From randomization up to 5 years (or until event, censoring, or study completion)

Other outcomes

  1. Agreement Between Investigator-Reported AEs and Patient-Reported PRO-CTCAE Symptoms

    Weighted kappa coefficient for concordance between investigator-graded adverse events (CTCAE) and patient-reported symptom severity/frequency measured by the PRO-CTCAE custom survey for selected symptoms (e.g., nausea, diarrhea, fatigue, joint pain). Detection rate and under-reporting rate will also be calculated.

    Time frame: From baseline through end of CDK4/6 inhibitor treatment period (up to 24-36 months)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 19 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2026
First posted
Jul 16, 2026
StartEst.
Nov 1, 2026was Aug 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2033
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Nov 1, 2026
Oct 27, 2026
Eligibility
3 inclusion criteria added, 3 removed
What changed in the criteria
Inclusion criteria
  • RemovedFor patients who received adjuvant chemotherapy: the last chemotherapy dose must be at least 21 days before randomization.
  • RemovedFor patients who received adjuvant radiotherapy: the last radiotherapy session must be at least 14 days before randomization.
  • RemovedThe last non-endocrine treatment (including surgery, radiotherapy, chemotherapy) must be within 90 days before randomization.
  • AddedFor patients who completed adjuvant or neoadjuvant chemotherapy(if applicable).
  • AddedFor patients who completed adjuvant radiotherapy(if applicable).
  • AddedFor patients who have initiated adjuvant endocrine therapy, randomization must be completed within 12 months of the first endocrine therapy administration date.
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Aug 1, 2026→Nov 1, 2026
    Eligibility 3 inclusion criteria added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedFor patients who received adjuvant chemotherapy: the last chemotherapy dose must be at least 21 days before randomization.
    • RemovedFor patients who received adjuvant radiotherapy: the last radiotherapy session must be at least 14 days before randomization.
    • RemovedThe last non-endocrine treatment (including surgery, radiotherapy, chemotherapy) must be within 90 days before randomization.
    • AddedFor patients who completed adjuvant or neoadjuvant chemotherapy(if applicable).
    • AddedFor patients who completed adjuvant radiotherapy(if applicable).
    • AddedFor patients who have initiated adjuvant endocrine therapy, randomization must be completed within 12 months of the first endocrine therapy administration date.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07706933
Responsible party
Zhenzhen Liu (Professor, Henan Cancer Hospital) — Principal investigator
First posted
Jul 16, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2033 (estimated)
Last update
Oct 27, 2026

Study contacts

Zhenzhen Liu
Contact
zlyyliuzhenzhen0800@zzu.edu.cn
13603862755

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalpiciclib

Start the discussion